MA50774A1 - Procédé de production d'un dérivé de diphénylméthane - Google Patents

Procédé de production d'un dérivé de diphénylméthane

Info

Publication number
MA50774A1
MA50774A1 MA50774A MA50774A MA50774A1 MA 50774 A1 MA50774 A1 MA 50774A1 MA 50774 A MA50774 A MA 50774A MA 50774 A MA50774 A MA 50774A MA 50774 A1 MA50774 A1 MA 50774A1
Authority
MA
Morocco
Prior art keywords
synthesis
linear
diphenylmethane derivative
production
route
Prior art date
Application number
MA50774A
Other languages
English (en)
Other versions
MA50774B1 (fr
Inventor
Hee-Kyoon Yoon
Se-Hwan Park
Ji-Sung Yoon
Soongyu Choi
Hee Jeong Seo
Eun-Jung Park
Younggyu Kong
Kwang-Seop Song
Min Ju Kim
So Ok Park
Original Assignee
Dae Woong Pharma
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma, Green Cross Corp filed Critical Dae Woong Pharma
Publication of MA50774A1 publication Critical patent/MA50774A1/fr
Publication of MA50774B1 publication Critical patent/MA50774B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/005Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un procédé amélioré de production d'un dérivé de diphénylméthane qui est efficace comme inhibiteur du cotransporteur du glucose dépendant du sodium (sglt), le procédé étant exécuté à l'aide d'un procédé de synthèse convergent dans lequel chaque groupe majeur est séparément synthétisé et ensuite couplé. Ainsi, comparativement à un procédé de synthèse linéaire présenté dans les documents existants, la voie de synthèse est compacte et le rendement peut être accru, et les facteurs de risque inhérents à la voie de synthèse linéaire peuvent être réduits. En outre, la forme cristalline du composé produit selon le procédé offre de superbes caractéristiques physico-chimiques, et ainsi peut être efficacement utilisée dans les domaines tels que la fabrication pharmaceutique.
MA50774A 2016-06-17 2017-06-15 Procédé de production d'un dérivé de diphénylméthane MA50774B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160075910 2016-06-17
PCT/KR2017/006271 WO2017217792A1 (fr) 2016-06-17 2017-06-15 Procédé de production d'un dérivé de diphénylméthane

Publications (2)

Publication Number Publication Date
MA50774A1 true MA50774A1 (fr) 2021-03-31
MA50774B1 MA50774B1 (fr) 2022-02-28

Family

ID=60664449

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44545A MA44545B2 (fr) 2016-06-17 2017-06-15 Procédé de production d'un dérivé de diphénylméthane
MA50774A MA50774B1 (fr) 2016-06-17 2017-06-15 Procédé de production d'un dérivé de diphénylméthane

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA44545A MA44545B2 (fr) 2016-06-17 2017-06-15 Procédé de production d'un dérivé de diphénylméthane

Country Status (29)

Country Link
US (2) US10640496B2 (fr)
EP (2) EP3663292B1 (fr)
JP (4) JP6763978B2 (fr)
KR (2) KR102233229B1 (fr)
CN (2) CN113651803B (fr)
AU (1) AU2017285813B2 (fr)
BR (1) BR112018076243A2 (fr)
CA (2) CA3081033C (fr)
CL (1) CL2018003645A1 (fr)
CO (1) CO2018014018A2 (fr)
DK (2) DK3663292T3 (fr)
DO (1) DOP2018000287A (fr)
EC (1) ECSP19000185A (fr)
ES (2) ES2898336T3 (fr)
HR (1) HRP20211670T8 (fr)
HU (1) HUE056428T2 (fr)
MA (2) MA44545B2 (fr)
MX (2) MX2021008988A (fr)
NZ (1) NZ749398A (fr)
PE (2) PE20240590A1 (fr)
PH (1) PH12018550206A1 (fr)
PL (2) PL3663292T3 (fr)
PT (2) PT3473621T (fr)
RS (1) RS62550B1 (fr)
SA (1) SA518400666B1 (fr)
SG (2) SG11201811154QA (fr)
SI (1) SI3663292T1 (fr)
TN (1) TN2018000437A1 (fr)
WO (1) WO2017217792A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011054773A1 (de) 2011-10-25 2013-04-25 Vb Autobatterie Gmbh & Co. Kgaa Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols
MX2021001732A (es) * 2018-08-13 2021-06-23 Daewoong Pharmaceutical Co Ltd Preparacion de intermedio util para la sintesis de inhibidor de sglt.
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
WO2021172955A1 (fr) 2020-02-27 2021-09-02 주식회사 대웅제약 Intermédiaire utile pour la synthèse d'un inhibiteur de sglt et procédé de préparation d'un inhibiteur de sglt l'utilisant
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
US20230322699A1 (en) 2020-09-10 2023-10-12 Daewoong Pharmaceutical Co., Ltd. Synthesis method for preparing sglt inhibitor intermediate
CN113200860A (zh) * 2021-04-29 2021-08-03 爱斯特(成都)生物制药股份有限公司 一种sglt2抑制剂中间体的制备方法
CN113801010A (zh) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 一种5-溴-2-氯苯甲酸的制备方法
CN113912487B (zh) * 2021-11-23 2024-05-28 山东研峰新材料科技有限公司 一种2,5-双卤代苯甲酸的合成方法
KR20230110001A (ko) * 2022-01-14 2023-07-21 주식회사 대웅제약 Ssglt 저해제의 합성에 유용한 중간체의 제조 방법
KR20240044190A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법
KR20240044194A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
DK2896397T4 (da) * 2003-08-01 2020-11-16 Mitsubishi Tanabe Pharma Corp Nye forbindelser med hæmmende aktivitet mod natriumafhængig glukosetransportør
EP2183263B1 (fr) 2007-07-26 2011-10-26 Lexicon Pharmaceuticals, Inc. Procédés et composés utiles pour la préparation d'inhibiteurs de co-transporteur 2 de sodium-glucose
AR075262A1 (es) 2008-07-30 2011-03-23 Ferrer Int Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno, proceso para prepararlos, composicion farmaceutica que los comprende, sus usos como medicamentos, o en tratamientos o prevenciones de condiciones asociadas con un funcionamiento alterado de los sistemas regulados por la melatonina, sus usos para
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012041898A1 (fr) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
US9034921B2 (en) * 2011-06-01 2015-05-19 Green Cross Corporation Diphenylmethane derivatives as SGLT2 inhibitors
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
SA518400666B1 (ar) 2021-11-30
ES2891825T3 (es) 2022-01-31
DK3473621T3 (da) 2021-09-06
ES2898336T3 (es) 2022-03-07
JP2023145481A (ja) 2023-10-11
MA50774B1 (fr) 2022-02-28
US10889574B2 (en) 2021-01-12
CL2018003645A1 (es) 2019-03-22
AU2017285813B2 (en) 2020-02-06
RU2021129636A (ru) 2021-11-22
ECSP19000185A (es) 2019-01-31
PE20240590A1 (es) 2024-03-21
CA3026756A1 (fr) 2017-12-21
SI3663292T1 (sl) 2022-01-31
MX2018015647A (es) 2019-04-11
HRP20211670T8 (hr) 2022-03-18
PL3663292T3 (pl) 2022-01-17
KR20210036892A (ko) 2021-04-05
WO2017217792A1 (fr) 2017-12-21
US20190169174A1 (en) 2019-06-06
JP7352509B2 (ja) 2023-09-28
MA44545A1 (fr) 2019-10-31
EP3663292A1 (fr) 2020-06-10
NZ749398A (en) 2020-01-31
US10640496B2 (en) 2020-05-05
CN113651803A (zh) 2021-11-16
JP2021152054A (ja) 2021-09-30
CO2018014018A2 (es) 2019-03-08
TN2018000437A1 (en) 2020-06-15
MA44545B2 (fr) 2020-11-30
RU2019101056A3 (fr) 2020-07-17
HUE056428T2 (hu) 2022-02-28
MA44545B1 (fr) 2020-05-29
DK3663292T3 (da) 2021-10-25
EP3663292B1 (fr) 2021-09-01
EP3473621B1 (fr) 2021-08-04
JP2020117528A (ja) 2020-08-06
KR102379584B1 (ko) 2022-03-29
KR20170142904A (ko) 2017-12-28
SG11201811154QA (en) 2019-01-30
CN109311861A (zh) 2019-02-05
JP2019521985A (ja) 2019-08-08
DOP2018000287A (es) 2019-03-31
JP6763978B2 (ja) 2020-09-30
PT3663292T (pt) 2021-11-08
PH12018550206A1 (en) 2019-09-30
KR102233229B1 (ko) 2021-03-29
CA3026756C (fr) 2021-03-02
BR112018076243A2 (pt) 2019-03-26
CN113651803B (zh) 2022-10-28
EP3473621A4 (fr) 2020-03-11
HRP20211670T1 (hr) 2022-02-18
CA3081033A1 (fr) 2017-12-21
CA3081033C (fr) 2022-04-12
US20190382390A1 (en) 2019-12-19
PL3473621T3 (pl) 2022-01-10
MX2021008988A (es) 2022-05-05
EP3473621A1 (fr) 2019-04-24
RS62550B1 (sr) 2021-12-31
CN109311861B (zh) 2021-08-24
AU2017285813A1 (en) 2019-01-17
SG10201911782RA (en) 2020-02-27
RU2019101056A (ru) 2020-07-17
PE20190467A1 (es) 2019-04-04
PT3473621T (pt) 2021-10-04

Similar Documents

Publication Publication Date Title
MA50774A1 (fr) Procédé de production d'un dérivé de diphénylméthane
EA201200117A1 (ru) Способ получения водной суспензии органического пестицидного соединения
MA32510B1 (fr) Procede pour l'extraction d'acides gras à partir de biomasse algale
MA33368B1 (fr) Préparation de chlorhydrate de nalmefene à partir de naltrexone
EP3929187A3 (fr) Procédé de production de composé de pyrrole
CR8975A (es) Proceso para la produccion de derivados de amina opticamente activos
MA48798B1 (fr) Procédé de production d'ozanimod
MA31325B1 (fr) Nouveaux procedes
MA30079B1 (fr) Procede de synthese de ferri-succinylcaseine
MA32530B1 (fr) Dérivés de spirocétals cristallins et procédé pour la préparation de dérivés de spirocétals
FR2895406B1 (fr) Procede pour la fabrication de 2,3-dimethylbut-1-ene
EP1954134A4 (fr) Procede de synthetisation de derive 2-phenyl-1h-phenantrho[9,10-d]imidazole
SE0302029D0 (sv) Novel process
PH12021550297A1 (en) Preparation of intermediate useful for synthesis of sglt inhibitor
MA40798A1 (fr) Amines modifiées utiles comme inhibiteurs d'incrustations dans une production d'acide phosphorique par voie humide
FR3000641B1 (fr) Nucleon pour la culture de perles et son procede de preparation
BRPI0514000A (pt) método para a produção de derivados de diarilcicloalquila
MA35806B1 (fr) Nouveau procede de synthese du 3-(2-bromo-4,5-dimethoxyphenil) propanenitrile, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
ATE517890T1 (de) Verfahren zur herstellung von reinem irbesartan
BR132019017038E2 (pt) processo de obtenção de espilantol
MA38535A1 (fr) Procédé de production d'acide 5-aminolévulinique ou d'un sel de celui-ci
PL439738A1 (pl) Sposób wytwarzania 4',5-dihydroksy-7-O-β-D-(4''-O-metyloglukopiranozylo)-izoflawonu
PL436250A1 (pl) 7-Metoksy-8-O-β-D-(4''-O-metyloglukopiranozylo)-flawon i sposób wytwarzania 7-metoksy-8-O-β-D-(4''-O-metyloglukopiranozylo)-flawonu
FR3122845B3 (fr) Fabrication de Produits Auto-Obturants à partir des Matières d’Une Composition d'élastomère Auto-obturante
FR2860230B1 (fr) Nouveau procede de preparation du cis-octahydro-isoindole